ETF Holdings Breakdown of LENZ

LENZ institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-29	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	8,103	USD 363,744
2025-09-29	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	16,174	USD 726,051 6.4%
2025-09-29	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	16,174	USD 726,051 6.4%
2025-09-29	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	503	USD 22,580 6.4%
Total =		40,954	USD 1,838,426

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with LENZ

TD Asset Management Inc Sells 68,172 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

TD Asset Management Inc decreased its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 66.2% during the first quarter, Holdings Channel reports. The firm owned 34,828 shares of the company’s stock after selling 68,172 shares during the quarter. TD Asset Management Inc’s holdings in LENZ Therapeutics were worth $895,000 as of […] - 2025-08-05 04:37:17

Noteworthy Wednesday Option Activity: META, CVNA, LENZ

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Meta Platforms Inc (Symbol: META), where a total volume of 348,474 contracts has been traded thus far today, a contract volume which is representative of approxi - 2025-07-16 17:13:46

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of “Buy” by Analysts

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been assigned an average rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year […] - 2025-06-26 03:10:50

Harbor Capital Advisors Inc. Has $1.25 Million Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Harbor Capital Advisors Inc. grew its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 10.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,616 shares of the company’s stock after purchasing an additional 4,627 shares during the period. Harbor Capital Advisors Inc. […] - 2025-06-13 05:18:56

Jane Street Group LLC Cuts Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Jane Street Group LLC lessened its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,938 shares of the company’s stock after selling 4,089 shares during the quarter. Jane Street Group LLC’s holdings in […] - 2025-06-05 04:15:01

The Manufacturers Life Insurance Company Raises Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

The Manufacturers Life Insurance Company grew its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 116.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 67,891 shares of the company’s stock after buying an additional 36,582 shares during the period. The Manufacturers […] - 2025-05-12 05:36:48

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of “Buy” by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been given an average recommendation of “Buy” by the six analysts that are currently covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 […] - 2025-05-07 02:34:51

Geode Capital Management LLC Sells 3,998 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Geode Capital Management LLC cut its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 334,026 shares of the company’s stock after selling 3,998 shares during the period. Geode Capital […] - 2025-04-24 04:24:51

LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.5% – Here’s Why

LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report)’s share price fell 8.5% during trading on Monday . The company traded as low as $18.81 and last traded at $19.38. 351,716 shares traded hands during trading, an increase of 104% from the average session volume of 172,211 shares. The stock had previously closed at $21.18. Analyst […] - 2025-04-08 04:56:51

Bank of New York Mellon Corp Trims Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Bank of New York Mellon Corp cut its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 29,214 shares of the company’s stock after selling 428 shares during the quarter. Bank of New York Mellon Corp’s holdings in LENZ Therapeutics were […] - 2025-03-26 05:52:54

TD Cowen Initiates Coverage on LENZ Therapeutics (NASDAQ:LENZ)

Equities research analysts at TD Cowen began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $60.00 price target on the stock. TD Cowen’s price target would suggest a potential upside of 135.11% from the company’s […] - 2025-03-20 04:48:55

Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40

LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) has earned an average rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target […] - 2025-02-06 04:06:45

Back to Listing

Disclaimer